Brimonidine tartrate eye drops
Function and Efficacy
This drug is a relatively selective α2 adrenergic receptor agonist for ophthalmic use. It has little effect on cardiovascular and pulmonary function. The intraocular pressure lowering effect reaches its peak two hours after administration. Studies using fluorescence spectrophotometry in animals and humans have shown that brimonidine tartrate has a dual mechanism of action; it reduces the production of aqueous humor and increases the outflow of the uveosclera.
Ingredients
Brimonidine tartrate.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| Brimonidine TartrateIngredients |
A relatively selective α2 adrenergic receptor agonist for ophthalmic use, with minimal effect on cardiovascular and pulmonary function, and peak intraocular pressure lowering effect two hours after administration, with a dual mechanism of action; both reducing aqueous humor production and increasing uveoscleral outflow. More |
70359-46-5 | 33 |
Indication
This product is suitable for reducing intraocular pressure in patients with open-angle glaucoma and ocular hypertension
Usage and Dosage
The usual dose is to instill 1 drop into the patient's eye 2 times a day. If the condition cannot be well controlled, 1 drop can be added in the afternoon.
Adverse Reactions
Approximately 1030% of the subjects experienced the following adverse reactions, in descending order, including dry mouth, eye congestion, burning and stinging sensation, headache, blurred vision, fatigue/tiredness, conjunctival follicles, ocular allergic reaction and ocular itching. Approximately 39% of the subjects experienced the following adverse reactions, in descending order, including corneal staining/erosion, photophobia, eyelid erythema, eye soreness/pain, dry eyes, tearing, upper respiratory tract symptoms, eyelid edema, conjunctival edema, dizziness, blepharitis, eye irritation, gastrointestinal symptoms, weakness, conjunctival blanching, abnormal vision and muscle pain. Less than 3% of the patients experienced the following adverse reactions, including eyelid crusting, conjunctival hemorrhage, abnormal taste, insomnia, increased conjunctival secretions, depression, hypertension, anxiety, palpitations, dry nose and syncope.
Precautions
This product is contraindicated in patients who are allergic to bronidine tartrate or any of its ingredients, and is also contraindicated in patients receiving treatment with monoamine chlorination inhibitors.
Drug Interactions
Although no specific studies have been conducted on drug interactions of this product, the possibility of additive or potentiating effects with central nervous system depressants (alcohol, barbiturates, opiates, sedatives or anesthetics) should be considered. Clinical studies have not found that this product has a significant effect on pulse or blood pressure, but since α-receptor agonists can also slow the pulse or increase blood pressure, attention should also be paid to the use of antidepressants and/or cardiotonic drugs. Literature reports that tricyclic antidepressants weaken the antihypertensive effect of systemic clonidine. Whether the simultaneous use of such drugs will interfere with the hypotensive effect of this product is not yet clear. There is no data on whether the use of this product will affect the high level of circulating catecholamines. However, when patients take tricyclic antidepressants that can affect the metabolism or uptake of circulating amines,
Packaging Specification
5 ml: 10 mg